We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DAS181

News List

Doubt cast over Avigan (favipiravir) and DAS181 potential to fight COVID-19 europeanpharmaceuticalreview
May 15, 2020
A new report has highlighted that the early successes of Avigan (favipiravir) and DAS181 do not guarantee their efficacy against COVID-19.
Ansun Biopharma Enrolls First Patient in Proof of Concept Trial of DAS181 for the Treatment of COVID-19 prnasia
April 15, 2020
Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patient in a proof-of-concept study to evaluate the safety and efficacy of DAS181, the Company's investigational recombinant sialidase for the t
Ansun Biopharma Announces Positive Results for Novel COVID-19 Treatment americanpharmaceuticalreview
April 07, 2020
Ansun Biopharma announced preliminary data from an investigator-initiated trial of DAS181, a recombinant sialidase with broad antiviral properties, for the treatment of severe COVID-19 infection.
Ansun BioPharma Announces Breakthrough Designation for DAS181 americanpharmaceuticacreview
October 12, 2017
PIV infection causes significant morbidity and mortality in immunocompromised patients as well as hospitalized patients, and currently there are no treatments available for patients infected with PIV.